UK markets open in 31 minutes

Alector, Inc. (ALEC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
17.51+0.44 (+2.58%)
At close: 04:00PM EST
17.51 0.00 (0.00%)
After hours: 05:39PM EST
Sign in to post a message.
  • O
    Oscar
    February 2019 Alector IPO USD 19.
  • A
    Alpha
    Wow right back to where they were before the billion dollars lol
  • k
    kastenz
    Ph 3 is the most 'developed' therapy being developed in trials. But it is only enrolling at this time, early Dec 2021.
  • O
    Oscar
    Lots of updates progress being made by Alector. Looks very promising 👍
  • Y
    Yahoo Finance Insights
    Alector is up 7.77% to 21.37
  • Y
    Yahoo Finance Insights
    Alector is down 9.69% to 18.65
  • J
    Jeffrey
    Sh be popping this wk.
  • D
    Douglas W.
    I think that ALEC will indeed be Jeff Brown’s #1 timed stock for 2021. Every indication points in that direction after reading his research report.
  • O
    Oscar
    Chief Operating Officer and Chief Medical Officer resigning at the same time is a serious point of worry and will have negative influence on the share price short term. What would be the real reason them stepping down.
  • J
    John1
    It's VERY interesting to see that Wehner David M.- an ALEC Director, purchased 20,000 shares yesterday (2-3-2020 date of trade) at $25 per seeing as it wasn't that low all day. He did not appear to use vesting options either. It's also interesting to see it's the day before the huge spike up over 7% so far today. What's up with this trade? Hmmmm
  • O
    Oscar
    Alector corporate portfolio update on their website 👍
  • C
    Cole
    So I bought some when it was on its way up, will it keep going or are we thinking it dips?
  • T
    Tomasz
    if Prevail Therapeutics is aquired by Lilly for max 1.04 b. with pipeline of 4 drugs in early clinical, Alector with 15 drugs which some of late clinical phase seems to be undervalued for 1.2 B. Alector is my main stock till buyout. in January probably start of phase II for Alzheimer :D
  • J
    Jeff
    It’s just a presentation of the study methodology and the biomarkers no conclusions or data included yet
  • M
    McManus
    it's all about the science folks. if results are good this stock is a coiled spring... it's dirt cheap next to avxl, dnli and sava. dnli is a quality outfit but avxl and sava are a bit shady. Alec is super high quality with a huge cash reserve, multiple shots on goal and two major pharma collaborations. we just need to see more out of the clinic.
  • R
    Roshan
    watch SAVA, same business as of Alector
  • R
    Ryan
    looks like mm's are waiting to get past feb 21st options expiration before they launch and double alec, everybody adjusted to that though and ut the same amount on next month also, stok alec goss dtil and vivo all needed that from the same manipulation tactics and games.
  • T
    TheBlindHog
    Looking at the separation agreements, Shehnaaz Suliman continues in an "at will" capacity until the end of the calendar year at her current salary and the company has agreed to carry over her indemnification insurance and liability insurance after she separates.

    Whereas, Robert Paul suffers an immediate reduction in salary upon the beginning of the transition period, being paid $1,730.77 per week from then until termination and there is no provision to continue indemnification and liability insurance.

    Suliman's agreement contains a "No Actions or Claims" clause, in which she avers she does not currently have pending in her name any charges, complaints, grievances, arbitrations, lawsuits, or claims against the Company, with any local, state or federal agency, union or court.

    Paul's letter does not have a No Actions or Claims clause.

    Suliman's agreement is silent on her performance based awards whereas Paul's letter states he has three (3) months following his Separation Date to exercise all vested options under the Grants; following the expiration of three (3) months following the Separation Date, all vested, but unexercised, options under the Grants shall be forfeited and he shall have no further right, title, or interest in the vested options.

    Looking at the disparity of terms in the separation agreements, it appears Robert Paul has committed an unknown transgression or malfeasance. Reading the tea leaves, it appears Suliman knew or should have known of the transgression and failed to act properly. That leads me to believe the transgression likely was related to the company business and was in the conduct of his role as chief medical officer.
  • K
    Kei
    Two ALEC insiders sold many shares for $20 ea. back on the 2oth. Check the chart since. Interesting to say the least.
  • c
    casey
    alector is going up. steadily.